Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliapixant in symptomatic endometriosis
NCT04614246Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of eliapixant in endometriosis (5 arms), sponsored by Bayer. Primary endpoint: Absolute Change in Mean Worst Endometriosis Associated Pelvic Pain (EAPP) at 12 weeks. Started Jan 2021; status: terminated.
02
Drugs
eliapixant
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT04614246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614246.